〔Abstract〕 Objective To investigate the clinical effect of sarcobactrum valsartan sodium combined with Shengui Huxin decoction in the treatment of chronic heart failure (CHF). Methods A total of 32 CHF patients treated in Xuchang Municipal Hospital from January 2019 to February 2020 were randomly numbered from 1 to 32. The odd numbers were assigned to the control group, and the even numbers were assigned to the observation group, with 16 cases in each group. Both groups were given conventional treatment. On this basis, the control group was treated with sarcobactrum valsartan sodium, and the observation group was treated with sarcobactrum valsartan sodium combined with Shengui Huxin decoction. Traditional Chinese mediciner (TCM) syndrome scores, cardiac function indexes, exercise endurance and quality of life of the two groups were compared before treatment and 2 months after treatment. Results After 2 months of treatment, the TCM syndrome scores of the both groups were lower than those of before treatment, and the observation group were lower than those of the control group, the differences were statistically significant (P < 0.05). After 2 months of treatment, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), Minnesota heart failure quality of life questionnaire (MLHFQ) scores in the observation group were lower than those in the control group, left ventricular ejection fraction (LVEF) and 6 min walking test (6 MWT) were all higher than those of the control group. The differences were statistically significant (P < 0.05). Conclusion Sarcobactrum valsartan sodium combined with Shengui Huxin decoction can improve the clinical symptoms and cardiac function, enhance exercise endurance, improve the quality of life of CHF patients.